Posts by Yi-Bin Chen, MD
-
Enasidenib Safe, Well Tolerated As Maintenance After Stem Cell Transplantation for IDH2-Mutated Myeloid Malignancies
Amir T. Fathi, MD, Yi-Bin Chen, MD, Zachariah DeFilipp, MD, Areej El-Jawahri, MD and colleagues found in a phase 1 trial that enasidenib 100 mg/day was safe and well tolerated as maintenance therapy for IDH2-mutated myeloid malignancies after hematopoietic cell transplantation and showed preliminary clinical activity.
-
Ivosidenib Shows Promise As Maintenance Therapy for AML After Bone Marrow Transplant
Amir T. Fathi, MD, Yi-Bin Chen, MD, Zachariah DeFilipp, MD, Areej El-Jawahri, MD and colleagues found in a phase 1 trial that ivosidenib was safe and well tolerated as maintenance therapy for acute myeloid leukemia following allogeneic hematopoietic cell transplantation, and two-year outcomes were promising.
Biography
Yi-Bin Chen grew up in New Jersey. He majored in molecular biophysics and biochemistry, earning a B.S./M.S. at Yale University before attending medical school at Harvard Medical School. Subsequently, he did his internship and residency at Massachusetts General Hospital, including an additional year as Chief Resident. This was followed by a fellowship in hematology/oncology at the Dana-Farber Mass General Brigham combined program. In 2008, he joined the staff of the Blood & Marrow Transplant (BMT) Program at the Mass General Cancer Center, has served as Director of Clinical Research since 2012 and was named overall Program Director in 2016. His interests mainly revolve around improving the outcomes of patients undergoing autologous and allogeneic stem cell transplantation. He has led original clinical trials involving all aspects of BMT, including conditioning regimens, alternative graft sources, novel approaches concerning the prevention and therapy of acute and chronic graft-vs-host disease (GVHD) and the use of maintenance therapies after BMT. He collaborates extensively with local and national colleagues as well as industry in addition to developing his own original clinical trials. He currently lives in Needham, MA with his wife and two children.
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
